BRIEF published on 09/08/2026 at 07:35, 5 days 7 hours ago MEMSCAP reduces its capital by cancelling shares Profitability Financial Strategy Capital Reduction MEMSCAP Actions Cancelled
BRIEF published on 09/08/2026 at 07:35, 5 days 7 hours ago MEMSCAP annule 105 483 actions pour réduire son capital social. Rachat D'actions Stratégie Financière MEMSCAP Réduction Du Capital Aérospatiale Et Médicale
BRIEF published on 09/08/2026 at 07:10, 5 days 8 hours ago Sandoz Boosts Biosimilar Production with New Facility in Slovenia Investment Capacity Expansion Sandoz Biosimilar Manufacturing Slovenia Facility
BRIEF published on 09/08/2026 at 07:10, 5 days 8 hours ago Sandoz augmente sa production de biosimilaires grâce à une nouvelle usine en Slovénie Investissement Sandoz Extension De Capacité Fabrication De Biosimilaires Installations En Slovénie
BRIEF published on 09/08/2026 at 07:05, 5 days 8 hours ago Sandoz Reveals Bio100 Ambition at Capital Markets Day Growth Strategy Investor Day EBITDA Margin Biosimilars Bio100
BRIEF published on 09/08/2026 at 07:05, 5 days 8 hours ago Sandoz dévoile son ambition Bio100 lors de la Journée des marchés financiers Stratégie De Croissance Marge D'EBITDA Biosimilaires Journée Des Investisseurs Bio100
BRIEF published on 09/08/2026 at 07:05, 5 days 8 hours ago Newron Secures EUR 5.5 Million in Share Subscription Share Subscription Newron Pharmaceuticals Phase 3 Study Treatment-resistant Schizophrenia Evenamide Program
BRIEF published on 09/08/2026 at 07:05, 5 days 8 hours ago Newron obtient 5,5 millions d'euros de souscription d'actions Newron Pharmaceuticals Partager L'abonnement Étude De Phase 3 Schizophrénie Résistante Au Traitement Programme Evenamide
BRIEF published on 09/08/2026 at 06:35, 5 days 8 hours ago Oerlikon's Ambitious Mission 2030 Financial Targets Innovation Financial Targets Sales Growth Oerlikon Mission 2030
BRIEF published on 09/08/2026 at 06:35, 5 days 8 hours ago Objectifs financiers ambitieux d'Oerlikon pour 2030 Innovation Objectifs Financiers Croissance Des Ventes Oerlikon Mission 2030
Published on 09/12/2026 at 02:35, 1 day 12 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 16 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 18 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 22 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 21 hours 35 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 7 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 17 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 17 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 19 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 8 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 days 8 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days 19 hours ago Availability of the 2026 Interim Financial Report
